Targeting the evolution of drug resistance in lung cancer
Even in their intended disease subset, Epithelial Growth Factor Receptor tyrosine kinase inhibitors leave behind residual disease eventually resulting in acquired resistance. Our study indicates that this process is driven by Aurora Kinase A. Inhibition of Aurora signaling may prevent the onset of a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-09-01
|
| Series: | Molecular & Cellular Oncology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/23723556.2019.1603092 |